Background. Intermittent preventive treatment in infants (IPTi) is the administration of sulfadoxinepyrimethamine (SP) at 2, 3, and 9 months of age to prevent malaria. We investigated the influence of IPTi on drug resistance.
Intermittent preventive treatment in infants (IPTi) consists of treatment doses of an antimalarial at the time of routine vaccinations in the first year of life. IPTi can reduce malaria and anemia in young children in malaria-endemic countries [1] , but concerns remain about its effect on drug resistance.
IPTi has been associated with increases in resistant parasites among recipients [2] [3] [4] , although this is not a consistent finding [5] . More important, however, is the effect of IPTi on the spread of resistance through the whole population. Models suggest only a small effect at this level [6, 7] , but this has not been evaluated in the field. We measured the impact of IPTi with sulfadoxine-pyrimethamine (SP) on population-wide resistance in a setting of high malaria endemicity in southern Tanzania.
There is no established method for the evaluation of the effect of public health interventions on the spread of resistance. It is important to test the effects over as many replicates as possible, to reduce the likelihood of confounding due to an imbalance between intervention and comparison arms. The optimal size of each replicate is not known: they should be large enough to ensure that contaminating gene flow between intervention and comparison areas does not obscure selection of resistant parasites but not so large that the evaluation becomes unfeasible or the parasite populations in different replicates are so unrelated they are incomparable. This suggests a need for baseline studies of genetic exchange between replicates, which we did using neutral microsatellite markers.
The drug recommended for IPTi is SP, a coformulation of competitive inhibitors of the folate biosynthesis enzymes dihydropteroate synthase (DHPS; inhibited by sulfadoxine) and dihydrofolate reductase (DHFR; inhibited by pyrimethamine). Resistance to SP is conferred by substitutions within the active site of target enzymes, as inferred by in vitro studies [8] [9] [10] [11] [12] , by the predictive association of particular mutations with treatment failure [13] [14] [15] , and from overrepresentation of mutations in recrudescent infections after treatment [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . In both enzymes, increasing numbers of substitutions confer increasing levels of insensitivity to drug, with single-or double-mutant dhfr alleles being mildly resistant while the triple-mutant dhfr allele is highly resistant. The combination of the dhfr triple-mutant N51I + C59R + S108N (CIRN) and the dhps double-mutant A437G + K540E (SGE) predicts failure of SP treatment [13] [14] [15] . Drug pressure arising from IPTi-SP can be assessed in a number of ways. First, blood specimens from a representative sample of people living in intervention and comparison areas can be tested for sulfadoxine; the proportion of positive blood spots reflects drug pressure in the different populations.
Second, dhfr and dhps resistance mutations can be tracked in intervention and comparison areas. If gene frequencies measured at baseline are similar in the 2 arms, then direct comparison of frequencies at follow-up indicates the differing degrees of selection. Estimation of the selection coefficient of key resistance alleles in intervention and comparison areas provides a measure of the rate of change of gene frequencies.
The third approach is to estimate the linkage disequilibrium between different dhfr and dhps alleles, in particular the dhfr triple-mutant CIRN and the dhps double-mutant SGE. These 2 alleles independently segregate on 2 different chromosomes but can be maintained in linkage disequilibrium by drug selection despite recombination, because of the improved survival of the combined CIRN +SGE genotype.
By using these approaches, we report a communityrandomized study that evaluated the extent to which IPTi increased drug pressure and the selection of resistant parasites.
METHODS

Study Area
The study was conducted in 5 districts of southern Tanzania [27] , with a total population of approximately 900 000 individuals, including approximately 23 400 infants. The districts are subdivided into 24 administrative areas, called divisions. IPTi was randomly assigned to 12 divisions [28] , leaving 12 divisions as controls, and unblinded IPTi implementation started in all 62 vaccinating health facilities in intervention divisions in April 2005. Tablets of SP were offered to children attending facilities for routine vaccinations with diphtheriatetanus toxoid-acellular pertussis, hepatitis B virus, and oral poliovirus vaccine, at approximately 2 and 3 months of age, and a third dose was offered when attending for measles vaccination, at about 9 months of age. Children weighing <5 kg received a quarter tablet of Fansidar, and those weighing ≥5 kg received a half tablet of Fansidar; 1 tablet contains 500 mg of sulfadoxine and 25 mg pyrimethamine. In 2006, a minimum estimate of 47% of neonates aged 6-11 months had received at least 2 doses of IPTi, with a maximum of 76% having received at least 1 dose in IPTi areas [28] .
At study start, first-line treatment for malaria was SP, but this changed in 2006 to artemether-lumefantrine (ALu) which became available after the 2006 survey. Diagnostic facilities were only available at approximately 10% of health facilities, so the majority of malarial diagnoses were made presumptively.
Household Surveys
Cross-sectional surveys in a representative cluster sample of households from the 24 divisions were conducted in JulyAugust 2004 (baseline) and July-August 2006 (follow-up). A third survey was conducted during July-November 2007. The baseline [27] and 2006 [28] surveys are described in detail elsewhere. In brief, all residents in 8 clusters of 30 households were sampled from each division for blood sampling. Each household in a division had an equal chance of inclusion, and no substitute household was included if residents were repeatedly absent or did not wish to participate. A modular questionnaire was administered using personal digital assistants (PDAs) [29] . Participants of all ages were invited to attend a measuring station located in the middle of the village, where a sample of blood was collected by finger prick and tested for Plasmodium falciparum malaria parasitemia, using the HRP-II-based Paracheck rapid diagnostic test (Orchid Biomedical Systems, Goa, India). A drop of blood was collected onto Whatman III filter paper. After air drying, filter papers were stored in ziplock plastic bags and shipped to the molecular laboratory for analysis. Sample sizes were amended for the 2006 and 2007 surveys, based on the prevalence of parasitemia and intracluster correlation coefficient of parasitemia in the previous survey. In 2006, this resulted in the random selection of 10 households per cluster for molecular studies. In 2007, sampling was stratified by age on the basis of the prevalence of parasitemia, such that all children aged 2-11 months, 12% of children aged 1-4 years, and 3% of children aged ≥5 years were sampled. This approach was expected to yield similar numbers of positive samples in each age group, and overall estimates of prevalence were weighted during the analysis according to the sampling fraction. Each survey was powered to estimate the prevalence of dhfr triple-mutant and dhps double-mutant alleles to within 15% of the true absolute prevalence in each trial arm. The 2006 and 2007 surveys each had 80% power to detect a change of ≥10 percentage points in the frequency of dhps double-mutant alleles from baseline.
High-Performance Liquid Chromatography (HPLC) Analyses
The quality of a representative number of tablets of Fansidar was assessed using HPLC as described previously [30] . A simple random sample of filter papers with adsorbed blood samples were analyzed for SP, using HPLC with photodiode array detection. Antimalarial drugs were extracted from the filter paper into methanol, and 20 µL was injected directly onto the HPLC column with gradient elution from 100% solvent A (20 mM ammonium formate; pH 2.7) to 100% solvent B (acetonitrile) over 15-25 minutes at a flow rate of 1.35 mL/minutes and a detector setting of 259 nm. Peak identity was confirmed by measuring the retention time, spiking the sample with commercially available standards, and determining the absorbance spectra by using the photodiode array detector. HPLC equipment and software were from Dionex (Camberley, United Kingdom). The sampling procedure was modified in the 2007 survey to account for the age stratification, with a simple random sample of 200 individuals per age group selected without considering the treatment arm from which the samples came.
SNP Genotyping
Blood spots from infected individuals were selected for analysis, with a maximum of 1 infected individual sampled at random per household. Parasite DNA was extracted using the chelex method [31] , and polymerase chain reaction (PCR)-based sequence-specific oligonucleotide probing (SSOP) at codons 436, 437, and 540 of dhps and codons 50, 51, 59 and 108 of dhfr was performed using methods described previously [31] . Samples taken during 2007 were sequenced using Big Dye V3.1 dye terminator sequencing and ABi 3730 DNA analyzer (Applied Biosystems, Foster City, CA). The same primers were used to preamplify dhfr for SSOP and direct sequence typing [31] Two additional primers were used in sequencing dhps [32] . A sample was considered to have a single haplotype when only 1 sequence variant was found at each locus. In mixed genotype infections, majority genotypes were recorded if their hybridization signal was twice that of the minority sequence. One haplotype only was counted from each infection, and mixed infections in which haplotypes could not be resolved were omitted from the frequency calculations.
Microsatellite Analysis
To describe the extent of gene flow between divisions, 6 microsatellite markers, PfG377, PfPk2, PolyA, ARA, TA109, and TA87, were amplified in baseline survey samples following a protocol previously described [33] . Amplification products were diluted a ratio of 1:100 into Hi Di formamide, run with LIZ-500 size standard on the ABi 3730 DNA analyzer (Applied Biosystems), and analyzed using Genemapper software (Applied Biosystems).
Multiplicity of infection was determined by counting the number of peaks observed at PolyA, PfPk2, and TA109 and calculating the average number of peaks across the 3 loci. This is a more conservative estimator of multiplicity of infection than taking the largest of the 3 values.
Molecular and HPLC laboratory analyses were conducted with laboratory workers blind to whether samples came from IPTi or comparison areas.
Data Processing and Analytical Methods
Palm m130 PDAs with 8 Mb RAM and running Pendragon Forms 4.0 software were used to enter data in the field. Automated range, consistency, and completeness checks were performed at the time of data entry. Particular attention was paid to the accuracy of dates because age is prone to recall errors.
Molecular and HPLC data analyses were performed in the statistical package R [34] . Analytical methods were those appropriate for cluster-randomized trials with a small number of clusters [35] , with statistical testing based on the t test, using a summary measure (eg, mean frequency) of the data from each of the 12 intervention and 12 comparison divisions. This adjusts both for the survey and study designs. Weighted t tests were used for comparisons across age strata of the HPLC data, using Bland's method [36] .
Population structure at the unlinked microsatellites for all pairwise comparisons of divisions was determined using the fixation index F ST , calculated in Arlequin [37] , and Nei's standard genetic distance [38] , calculated in Phylip [39] . F ST calculates the portion of expected heterozygosity that is attributable to population subdivision, whereas Nei's distance is based on allele frequency differences between populations. Both indices range between 0 and 1, with 0 indicating that populations are identical.
Ethics
The trial (clinical trials registration NCT00152204) was approved by local and national institutional review boards (the Ifakara Health Institute [formerly the IHRDC] and the National Tanzania Medical Research Co-coordinating Committee). Ethics and research clearance were also obtained from LSHTM and from the Ethics Commission of the Cantons of Basel-Stadt and Basel-Land, Switzerland. During field work, information sheets in Swahili were provided, and written informed consent was sought from the heads of all households. Figure 1 shows that parasite prevalence, multiplicity of infection, and the age-pattern of each was comparable in intervention and comparison divisions at each survey point. Parasite prevalence fell to a similar extent in both arms during the trial. Heterozygosity, a measure of genetic diversity, was high across the 24 divisions, with mean values ranging from 0.771 to 0.831. Pairwise F ST values ranged from <0 to 0.07 (only 5 comparisons were significantly >0), and Nei's standard genetic distance ranged from 0.031 to 0.139 (data available on request), indicating a high degree of genetic similarity among divisions. 
RESULTS
SP Detection
Resistance Alleles and Selection Coefficients
, the 581 dhps mutation was found in 0.5% of samples from the comparison arm but was absent from the intervention arm. A previously unidentified S436H substitution was found among 12 of the 394 samples sequenced for dhps in 2007.
The frequencies of the dhfr triple-mutant CIRN allele and the dhps double-mutant SGE haplotypes in each division are shown in Figure 3 . The general trend was for dhfr mutant frequencies to increase over time. The CIRN allele frequency was not different in the 2 study arms in 2004 (P = .89) or 2006 (P = .93), and SGE frequencies were also comparable between arms at these times (2004, P = .52; 2006, P = .54). However, in 2007, the CIRN allele frequency was higher in the intervention than in the comparison arm (P = .004). The frequency of the SGE allele was (nonsignificantly) higher in the intervention arm than in the comparison arm (P = .18).
The corresponding selection coefficients were similar in the 2 arms of the trial between 2004 and 2006 (Table 2) . However, the 2006-2007 SGE selection coefficient became negative, most markedly in the comparison arm.
To assess the specific impact of IPTi among infants, we compared resistance allele frequencies in subjects aged <1 year with those among subjects aged >1 year. There was some evidence that the frequency of resistance alleles was higher among those aged <1 year than in older age groups across both arms at all time points (Table 3 ). There was no discernible effect of IPTi on the frequency of resistance among subjects aged <1 year in the intervention arm. Among subjects aged ≥1 year, the only evidence of a difference in resistance allele frequencies was in 2007, when the CIRN allele frequency was 13 percentage points higher in the intervention arm (P = .034).
Linkage Disequilibrium
There was strong evidence of linkage disequilibrium between the dhfr triple-mutant CIRN and the dhps double-mutant SGE (Table 4) , with a statistically significant association in both arms at all 3 time points, except for the intervention arm in 2007.
DISCUSSION
We have described the impact of IPTi on the spread of resistance to SP at the population level. We monitored SP drug pressure, dhfr and dhps mutation frequencies, selection coeffi- months of IPTi implementation. Malaria transmission, reflected by parasite prevalence, multiplicity of infection, and the age-pattern of each, was comparable in IPTi and comparison areas throughout the study. There was considerable genetic diversity among parasites across the study area, and gene flow studies found no evidence of population subdivision between divisions. At baseline, the genetic determinants of SP resistance were present at similar frequencies in each study arm. Between 2004 and 2006, while SP was the first-line treatment for malaria infections and the drug used for IPTi, the frequency of the CIRN and SGE alleles increased at a comparable rate in both study arms. The overall prevalence of SP was 11%-13% and not different between the comparison and intervention arms. Thus, IPTi had no measurable effect on SP drug pressure over that generated by its widespread use for treatment, suggesting that the number SP doses used for IPTi was balanced by the number of SP treatments for illness episodes in comparison areas. IPTi may therefore be of greater value in areas where access to vaccination-based preventive services is better than access to drugs through curative services.
In late 2006, the national treatment policy with ALu was rolled out, and SP use decreased. However, the proportion of people aged >12 months who were positive for SP had changed little by the time of the 2007 survey, with SP detected in all age strata. There was a statistically significant decrease in detectable SP among individuals aged <12 months living in comparison areas, presumably because these infants were increasingly treated with ALu. In contrast, SP increased in infants where IPTi-SP continued.
The change in SP drug pressure in infants living in IPTi areas was associated with an overall increase in the frequency of the dhfr triple mutation and a corresponding 3-fold difference in the selection coefficient for the CIRN allele. This suggests a population-wide effect on P. falciparum genotypes of an intervention targeting children aged 2-9 months. In contrast, the dhps double-mutant frequencies stabilized in both comparison and intervention divisions following withdrawal of SP as first-line therapy, with a suggestion of a decrease in the comparison arm, in keeping with the notion that the SGE double mutant carries a fitness cost [40] .
The study has a number of limitations. We were limited to 12 intervention and 12 comparator divisions. Therefore, [28] . More pronounced effects may have been documented with longer follow-up or higher levels of coverage. Fourth, the use of HRP-II-based rapid diagnostic tests means that, because the HRP-II antigen persists after treatment, an individual may have been identified as parasite positive for >2 weeks after the infection had been effectively treated [41] . This resulted in a proportion of RDT-positive samples being PCR negative, reducing the number of samples contributing to analyses and the statistical power of the evaluation. However, both the geographical scale and the significant differences in selection pressures and haplotype frequencies between the study arms add plausibility to the evaluation. These results and conclusions are specific to SP in eastern Africa. The fitness costs of the SGE allele may be different in western Africa, where an alternative dhps allele is found [42] . In addition, the increase in frequency of resistance mutations is not linear, and this study was conducted when the baseline level of resistance was already high. The results may be different in settings with lower baseline resistance.
This study was conceived to evaluate the effect of IPTi-SP on the spread of SP resistance and the risk that IPTi-SP might undermine SP treatment efficacy. We have shown that IPTi-SP did not exacerbate the spread of resistance when delivered alongside SP for first-line malaria treatment. However, malaria treatment in many settings now depends on ACTs. When ACTs were introduced into the study area, the frequency of the dhfr triple mutant continued to climb, but the frequency of the dhps double mutant appeared to decrease. As treatment failure occurs primarily when dhfr triple is found in combination with dhps double, we conclude that IPTi-SP is unlikely to undermine SP treatment efficacy.
The World Health Organization has recommended that IPTi-SP be considered in areas of moderate or intense malaria transmission [43] , but not if the frequency of the 540 mutation-a marker of the quintuple mutation-is ≥50%. Many countries fulfilling the intensity criterion fail the resistance criterion [44] . Our study suggests that quintuple-mutation frequencies may fall once ACTs are deployed, and it draws attention to the need to monitor molecular markers of SP resistance where IPTi-SP may otherwise be useful for malaria control. 
Notes
